A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs AZD-1775 (Primary) ; Docetaxel; Pegfilgrastim
- Indications Lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Oct 2016 Results from lead-in portions of this and other study (n=46) presented at the 41st European Society for Medical Oncology Congress.
- 06 May 2016 Status changed from completed to discontinued.
- 10 Jun 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History